Advertisement

HindustanTimes Mon,22 Sep 2014

Pharma giant Novartis working on H7N9 vaccine

AFP  Geneva, April 25, 2013
First Published: 21:24 IST(25/4/2013) | Last Updated: 21:26 IST(25/4/2013)

Swiss pharmaceuticals giant Novartis is researching a vaccine for the H7N9 strain of bird flu, its chief executive said on Thursday, amid fears that the disease could mutate into a form that spreads among people.

Advertisement

In an interview with the Swiss daily Tagesanzeiger, Joe Jimenez said that Novartis had already analysed the virus' genetic codes, which have been published by Chinese authorities.

Jimenez said that Novartis "would today be in a position to develop a vaccine for initial clinical trials within six to eight weeks".

"The need is theoretical for now," he added.

Since the discovery of the first cases several weeks ago in China, a total of 108 people have been confirmed as being infected with the H7N9 virus, of whom 22 have died, marking the first time the strain has claimed human lives.

Officials from the World Health Organisation have underlined that the strain is therefore one of the deadliest of the many forms of flu carried by birds and posing various degrees of risk to humans.

On Wednesday, Taiwan recorded the first case outside China, in a man who had recently returned from working there.

There have been no recorded cases to human-to-human transmission, but the spectre of a form of the virus being able to jump between people has placed global health officials on alert.


Advertisement
more from Business

Airlines oppose govt policy on connectivity to remote areas

Airlines and private charter operators have opposed the government's draft policy on air connectivity to regional and remote areas, saying it will have severe impact on their financial strength.
markets
Advertisement
Most Popular
Advertisement
Advertisement
Copyright © 2014 HT Media Limited. All Rights Reserved